| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,824 |
4,995 |
$1.22M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,240 |
4,635 |
$1.19M |
| 99215 |
Prolong outpt/office vis |
920 |
821 |
$235K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
264 |
231 |
$53K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
108 |
107 |
$26K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
51 |
51 |
$12K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
31 |
31 |
$9K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
31 |
30 |
$7K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
128 |
105 |
$4K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
14 |
14 |
$3K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
156 |
150 |
$3K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
454 |
403 |
$1K |
| 96127 |
|
87 |
83 |
$914.99 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
45 |
44 |
$877.75 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
544 |
279 |
$825.26 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
133 |
126 |
$49.83 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
525 |
465 |
$43.61 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
111 |
101 |
$18.56 |
| 90686 |
|
131 |
130 |
$17.13 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
97 |
95 |
$10.84 |
| 81003 |
|
99 |
84 |
$1.91 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
124 |
118 |
$0.00 |
| 87634 |
|
207 |
184 |
$0.00 |
| 90461 |
|
16 |
15 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
32 |
31 |
$0.00 |
| 2010F |
|
15 |
15 |
$0.00 |